Release Date: 06.06.2013
Presentation Type: Webinars
Patients with Pulmonary Arterial Hypertension share similarities with those with myeloproliferative disorders. Hydroxyurea is used routinely in this group of patients and works by decreasing hematopoietic progenitors and peripheral counts. NHLBI researcher, Dr. Ronan Desmond, discusses a hypothesis that hydroxyurea could potentially improve hemodynamic parameters in PAH. He also discusses the pre-clinical work that led to this protocol’s conception and outlines details of its upcoming clinical trial.